# Cannabinoid Clinical Trials: Cannabis for Chronic Back Pain > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/full-spectrum-cannabis-extract-chronic-low-back-pain/ > **Published:** 2026-03-17T09:28:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:58:15-04:00 > **Clinical Summary:** Explore the full-spectrum cannabis extract chronic low back pain trial showing promising results for safe and effective pain management. --- #### Clinical Takeaway In this phase 3 trial of 820 adults with chronic [low back pain](https://cedclinic.com/dronabinol-placebo-controlled-trial-chronic-pain/), the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up periods reaching up to one year. The study design included both a randomized withdrawal phase, which helps establish whether benefits are sustained and causally linked to the treatment rather than natural disease fluctuation. Results from this rigorously controlled trial provide some of the highest-quality clinical evidence to date on cannabis-based treatment for one of the most prevalent pain conditions globally. ### #1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. **Citation:** Karst Matthias et al. *Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.* Nature medicine. 2025. PMID: 41023483. **Study type:** Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study  |  **Topic area:** Pain  |  **CED Score:** 14 Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2 **Quality Gate Alerts:** - Preclinical only **Methodological Considerations:** - Open-label design — placebo effect not excluded **Abstract:** Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total [neuropathic pain](https://cedclinic.com/cannabis-for-pain-relief/) symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04  |   |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41023483/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705446/)[DOI ↗](https://doi.org/10.1038/s41591-025-03977-0) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Sativa Extracts for Chronic Low Back Pain: A Phase 3 Randomized Trial](https://cedclinic.com/phase-3-cannabis-trial-chronic-low-back-pain-results/) Detailed results from a phase 3 [randomized trial](https://cedclinic.com/cannabis-cannabinoids-therapeutic-applications-review/) evaluating cannabis sativa extracts for chronic low back pain. [Read More](https://cedclinic.com/phase-3-cannabis-trial-chronic-low-back-pain-results/) [Endocannabinoid System & Chronic Low Back Pain: Phase 3 Trial Results on Cannabis Sativa Extracts](https://cedclinic.com/phase-3-randomized-controlled-trial-chronic-low-back-pain/) Explore the role of the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in chronic low back pain with phase 3 trial data on cannabis sativa extracts. [Learn More](https://cedclinic.com/phase-3-randomized-controlled-trial-chronic-low-back-pain/) [medical cannabis evidence-based care: Phase 3 Trial Results](https://cedclinic.com/phase-3-cannabis-trial-chronic-low-back-pain-results/) Comprehensive review of phase 3 trial results supporting evidence-based [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) care. [Discover More](https://cedclinic.com/phase-3-cannabis-trial-chronic-low-back-pain-results/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoid%20Clinical%20Trials%3A%20Cannabis%20for%20Chronic%20Back%20Pain&url=https%3A%2F%2Fcedclinic.com%2Ffull-spectrum-cannabis-extract-chronic-low-back-pain%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Ffull-spectrum-cannabis-extract-chronic-low-back-pain%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoid%20Clinical%20Trials%3A%20Cannabis%20for%20Chronic%20Back%20Pain%20https%3A%2F%2Fcedclinic.com%2Ffull-spectrum-cannabis-extract-chronic-low-back-pain%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).